Friday, January 04, 2013

FDA sends out warnings of unapproved Botox

A Canadian supplier has distributed unapproved Botox which could turn out to be "counterfeit or unsafe," according to the U.S. Food and Drug Administration.
The FDA sent out warning letters in December to more than 350 medical practices alerting them of danger, the Associated Press said. The letter noted that batches of the popular wrinkle treatment drug shipped by the pharmacy Canada Drugs haven't been approved by the federal agency. It added that Canada Drugs was also accused of shipping unapproved and counterfeit versions of the cancer drug Avastin in the past, the AP said.